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The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 5 million deaths worldwide. Pneumonia and systemic inﬂammation contribute to its high mortality. Many
viruses use heparan sulfate proteoglycans as coreceptors for viral entry, and heparanase
(HPSE) is a known regulator of both viral entry and inﬂammatory cytokines. We evaluated
the heparanase inhibitor Roneparstat, a modiﬁed heparin with minimum anticoagulant
activity, in pathophysiology and therapy for COVID-19. We found that Roneparstat signiﬁcantly decreased the infectivity of SARS-CoV-2, SARS-CoV-1, and retroviruses (human Tlymphotropic virus 1 [HTLV-1] and HIV-1) in vitro. Single-cell RNA sequencing (scRNA-seq)
analysis of cells from the bronchoalveolar lavage ﬂuid of COVID-19 patients revealed a
marked increase in HPSE gene expression in CD681 macrophages compared to healthy
controls. Elevated levels of HPSE expression in macrophages correlated with the severity
of COVID-19 and the expression of inﬂammatory cytokine genes, including IL6, TNF, IL1B,
and CCL2. In line with this ﬁnding, we found a marked induction of HPSE and numerous
inﬂammatory cytokines in human macrophages challenged with SARS-CoV-2 S1 protein.
Treatment with Roneparstat signiﬁcantly attenuated SARS-CoV-2 S1 protein-mediated
inﬂammatory cytokine release from human macrophages, through disruption of NF-k B
signaling. HPSE knockdown in a macrophage cell line also showed diminished inﬂammatory cytokine production during S1 protein challenge. Taken together, this study provides
a proof of concept that heparanase is a target for SARS-CoV-2-mediated pathogenesis
and that Roneparstat may serve as a dual-targeted therapy to reduce viral infection and
inﬂammation in COVID-19.
IMPORTANCE The complex pathogenesis of COVID-19 consists of two major pathological phases: an initial infection phase elicited by SARS-CoV-2 entry and replication
and an inﬂammation phase that could lead to tissue damage, which can evolve into
acute respiratory failure or even death. While the development and deployment of
vaccines are ongoing, effective therapy for COVID-19 is still urgently needed. In this
study, we explored HPSE blockade with Roneparstat, a phase I clinically tested HPSE
inhibitor, in the context of COVID-19 pathogenesis. Treatment with Roneparstat
showed wide-spectrum anti-infection activities against SARS-CoV-2, HTLV-1, and HIV1 in vitro. In addition, HPSE blockade with Roneparstat signiﬁcantly attenuated SARSCoV-2 S1 protein-induced inﬂammatory cytokine release from human macrophages
through disruption of NF-k B signaling. Together, this study provides a proof of principle for the use of Roneparstat as a dual-targeting therapy for COVID-19 to decrease
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viral infection and dampen the proinﬂammatory immune response mediated by
macrophages.
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CoV-2
oronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has quickly become a leading cause of death worldwide. In response to the rapid spread of COVID-19, a global effort has been poured
into the development of novel therapies for the prevention and treatment of the disease (1). Currently, therapeutic approaches for hospitalized patients with COVID-19 disease
include remdesivir, steroids, heparin, convalescent-phase plasma, and monoclonal antibodies, which have had some success, yet the mortality rate remains high in patients with
severe disease (2). In contrast to the great success in vaccine development, the progress for
effective COVID-19 treatment has been slower.
The complex pathogenesis of COVID-19 consists of two major pathological phases: (i) an
early infection phase, characterized by SARS-CoV-2 viral entry, replication, and spread, and
(ii) an inﬂammation phase, characterized by aberrant proinﬂammatory cytokine release that
leads to tissue damage, which can evolve into acute respiratory distress syndrome (ARDS)
and hypoxemia that may require mechanical ventilation (3). About 20% of COVID-19
patients progress to the severe/critical stage, featuring a marked increase in inﬂammatory
markers, including C-reactive protein, ferritin, and interleukin-6 (IL-6) (4). In these patients, a
“cytokine storm” or “cytokine release syndrome” (CRS) results from excessive noneffective
host immune responses by T cells and inﬂammatory monocytes, a phenomenon often seen
in patients receiving chimeric antigen receptor (CAR) T-cell therapy, and is associated with
mortality (5).
Similar to SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV),
the spike (S) glycoprotein is required for the entry of SARS-CoV-2 into host cells (6).
Because of the potent immune response that it elicits, the S protein has also been widely
used as the target antigen in COVID-19 vaccines (7). S protein-mediated SARS-CoV-2
entry is codependent on host angiotensin-converting enzyme 2 (ACE2) and heparan sulfate (HS); treatment with heparin or heparin derivatives can decrease SARS-CoV-2 entry
(8). Heparan sulfate proteoglycans (HSPGs) on the surface of cells are ubiquitously presented glycoproteins comprised of linear, negatively charged polysaccharide chains that
bind to a variety of soluble and insoluble cell surface or extracellular matrix proteins.
Many viruses, including herpes simplex virus 1 (HSV-1), dengue virus (DENV), human
papillomavirus (HPV), and human T-lymphotropic virus 1 (HTLV-1), exploit cell surface
HSPGs by utilizing them to attach to host cells (9).
The enzyme heparanase (HPSE) is the only known mammalian endoglycosidase capable
of degrading the heparan sulfate chains of HSPGs and regulating the expression of multiple
inﬂammatory cytokine genes (10, 11). Heparanase has been implicated in the pathogenesis of
multiple cancers and inﬂammatory diseases such as pancreatitis, colitis, and acute renal injury
(12, 13). In a model of murine experimental sepsis that results in a systemic inﬂammatory
response and acute lung injury, vascular hyperpermeability and ARDS were eliminated by
blocking heparanase degradation of the endothelial glycocalyx (14). In HSV-1-mediated
inﬂammatory disease, heparanase promotes viral shedding and release and triggers proinﬂammatory cytokine release (15). A recent clinical study reported an increase in plasma heparanase levels in COVID-19 patients, especially in patients with severe disease (16). However, the
contribution of heparanase to the pathogenesis of COVID-19 has not been fully characterized.
Due to the elevated expression of heparanase in cancers such as multiple myeloma
(MM), several heparanase inhibitors have been developed as anticancer therapies (10).
Roneparstat (SST0001) is a chemically modiﬁed, 100% N-acetylated, and glycol-split
heparin and a potent inhibitor of heparanase enzyme activity (IC50 [half-maximal inhibitory concentration] = 3 nM) (17). Glycol splitting of uronic acid residues within heparin
disrupts an essential glucuronic acid that lies within the heparin pentasaccharide
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RESULTS
The heparanase inhibitor Roneparstat decreases SARS-CoV-2 infectivity. Heparan
sulfate (HS) is an important cofactor for the attachment and entry of multiple viruses,
including SARS-CoV-2 (8, 9). To test whether Roneparstat could suppress SARS-CoV-2 S
protein-mediated entry, we ﬁrst used a replication-competent VSV-SARS-CoV-2 chimeric virus (VSV-eGFP-SARS-CoV-2), in which the VSV G gene was replaced by the
SARS-CoV-2 S gene (Fig. 1A). In this model, Vero-E6 cells were infected by VSV-eGFPSARS-CoV-2 (multiplicity of infection [MOI] = 0.1) in the presence of various doses of
Roneparstat or heparin for 1 h. At 10 h postinfection, green ﬂuorescent protein-positive
(GFP1) cells were quantiﬁed. Treatment with Roneparstat or heparin resulted in a signiﬁcant dose-dependent decrease in infected cells (Fig. 1B and C), with half-maximal
inhibitory concentrations (IC50s) of 0.05 m g/mL and 0.03 m g/mL, respectively (Fig. 1D
and E). Similar inhibitory effects on infectivity were observed in Vero-E6 cells infected
with the VSV-eGFP-SARS-CoV-1 chimeric virus in which VSV G was replaced with the
SARS-CoV-1 S gene (Fig. 1F to J), suggesting that Roneparstat and heparin inhibit cell
entry mediated by S protein.
We next examined the effect of Roneparstat and heparin during SARS-CoV-2 infection in Vero-E6 cells. Vero-E6 cells were infected with SARS-CoV-2 in the presence of
various doses of Roneparstat or heparin for 1 h. At 24 h postinfection, the cell culture
supernatant from each well was harvested for virus titration by a plaque assay on
Vero-E6 cells. SARS-CoV-2-infected Vero-E6 cells were immunostained with speciﬁc
anti-spike (S) or -nuclear (N) protein antibody (Fig. 1K and L). In line with what we
observed in the VSV-eGFP-SARS-CoV-2 infection assay, both Roneparstat and heparin
treatment signiﬁcantly decreased SARS-CoV-2 infection, with IC50s of 0.07 m g/mL and
0.05 m g/mL, respectively (Fig. 1M and N). Together, these data demonstrated that
Roneparstat is potent against SARS-CoV-2 infection in vitro.
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responsible for binding to antithrombin (18). The resulting diminished antithrombin
binding activity of the glycol-split heparin greatly diminishes its anticoagulant activity,
thus allowing the utilization of the drug at high doses in patients. At the preclinical
stage, Roneparstat also showed therapeutic beneﬁt in multiple inﬂammatory disease
models such as acute pancreatitis and acute kidney injury (19). In a phase I clinical trial
(ClinicalTrials.gov identiﬁer NCT01764880) in patients with advanced MM, Roneparstat
was well tolerated and safe at all doses tested, with no dose-limiting toxicities (20).
In this study, we set out to investigate the role of heparanase in the pathogenesis of
COVID-19 and evaluate Roneparstat as a novel therapy. In line with the role of HSPGs as
coreceptors for viral entry, we found that treatment with heparin or Roneparstat effectively
decreased the infectivities of SARS-CoV-2 as well as the retroviruses HTLV-1 and HIV-1 in
vitro. Using HIV-1Denv pseudotyped with vesicular stomatitis virus G (VSVg) envelope, an
HSPG-independent pseudotyped virus, we further showed that the antiviral activity of
Roneparstat is speciﬁc to HSPG-mediated viral entry. Single-cell RNA sequencing (scRNAseq) analysis of cells isolated from bronchoalveolar lavage ﬂuid (BALF) of COVID-19 patients
showed elevated levels of HPSE gene expression compared to healthy controls. In addition,
we found that HPSE expression was almost exclusively upregulated in CD681 macrophages
and correlated with disease severity and multiple inﬂammatory cytokine genes, including
IL6, IL1B, and TNF. In primary human macrophages, SARS-CoV-2 S protein challenge
induced the expression of HPSE and inﬂammatory cytokines. The knockdown (KD) of HPSE
in human macrophages attenuated the induction of multiple inﬂammatory cytokines by
SARS-CoV-2 S1 protein, suggesting that HPSE plays an important role in the induction of
these inﬂammatory cytokines in macrophages. We further demonstrated that heparanase
blockade with Roneparstat attenuated the production of the inﬂammatory cytokines in a
dose-dependent manner via disruption of NF-k B signaling. Overall, this study provides a
proof of principle for the use of Roneparstat as a dual-targeting therapy for COVID-19 to
decrease viral infection and dampen the proinﬂammatory immune response mediated by
macrophages.

Journal of Virology

FIG 1 The HPSE inhibitor Roneparstat suppresses coronavirus infection. (A) Schematic representation of
the genome of VSV-eGFP-SARS-CoV-2. VSV G was deleted from the VSV genome, and the SARS-CoV-2 S

(Continued on next page)
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Roneparstat blocks HSPG-dependent viral entry. To rule out that the reduction
of infectivity was due to the potential cytotoxicity of Roneparstat, we examined the viability of cells treated with various doses (up to 200 m g/mL) of Roneparstat. As measured by cell viability assays, no cytotoxicity was observed in multiple cell lines (VeroE6, Jurkat, and THP-1) treated with Roneparstat (Fig. 2A to C). HSPG is known as one of
the coreceptors for SARS-CoV-2 and HTLV-1 viral entry (8). Therefore, we further
extended our analysis to the infectivity of retroviruses, including HTLV-1 and HIV-1.
Jurkat T cells, engineered to express the luciferase (Luc) gene driven by the HTLV-1
long terminal repeat (LTR), were cocultured with the HTLV-1-producing cell line MT-2
for 48 h in the presence or absence of various doses of Roneparstat. Similarly, TZMBlue cells engineered to express luciferase driven by the HIV-1 LTR were pretreated
with various doses of Roneparstat and infected with HIV-1 for 24 h. In both experiments, Roneparstat treatment signiﬁcantly decreased infection by HTLV-1 (Fig. 2D) and
HIV-1 (both CXCR4- and CCR5-tropic strains) (Fig. 2E and F). Conversely, infection by
VSV is independent of the HSPG-mediated viral entry mechanism (21, 22). To conﬁrm
that the reduction of infectivity by Roneparstat was HSPG dependent, we constructed
HSPG-independent VSVg–HIV-1Denv pseudotyped virus by cotransfecting HIV-1-luc/
Denv (HIV-1 with defective envelope) with VSVg. CXCR4-expressing U87/X4 or CCR5expressing U87/R5 target cells were infected with VSVg-HIV-1Denv-luc in the presence
or absence of Roneparstat for 48 h. No reduction of infectivity was observed in either
U87/X4 or U87/R5 cells infected with VSVg-HIV-1Denv-luc (Fig. 2G and H), suggesting
that Roneparstat-mediated blockade of infectivity is through HSPGs. Together, these
data demonstrated that treatment with Roneparstat or heparin decreases the infectivity of a broad spectrum of viruses, including SARS-CoV-1, SARS-CoV-2, HTLV-1, and HIV1, in vitro through an HSPG-dependent viral entry mechanism.
Upregulation of heparanase expression in pulmonary macrophages from COVID19 patients. Increased plasma levels of heparanase were reported in COVID-19 patients
(16). Seeking to identify the cells that expressed the HPSE gene in COVID-19 patients,
we analyzed the single-cell RNA sequencing (scRNA-seq) data set (GEO accession number GSE145926) from cells harvested from the bronchoalveolar lavage ﬂuid (BALF) of
moderate or severe COVID-19 patients and healthy volunteers (23). HPSE gene expression was upregulated in various BALF cell populations of patients with COVID-19, especially those with severe COVID-19 (Fig. 3A). Speciﬁcally, HPSE was highly expressed in
the macrophage population (CD681), with modest increases in T cells (CD3D1), epithelial cells (TPPP31 KRT181), and myeloid dendritic cells (mDCs) (CD1C1 CLEC9A1) in
patients with severe COVID-19 compared to the healthy controls and those with moderate
disease (Fig. 3B). Further analysis of the CD681 macrophage population demonstrated that

FIG 1 Legend (Continued)
gene was inserted between the M and L genes in the VSV genome, which resulted in the construction of
replication-competent VSV-eGFP-SARS-CoV-2. Monolayers of Vero-E6 cells were infected with VSV-eGFPSARS-CoV-2 at an MOI of 0.1 in the presence or absence of various doses of Roneparstat or heparin for 1
h. At 10 h postinfection, infected cells (GFP1) were quantiﬁed by a Cytation 5 microscope. (B and C)
Representative ﬂuorescence images of Vero-E6 cells infected with VSV-eGFP-SARS-CoV-2 in the presence
of 0, 0.012, 0.2, and 3.125 m g/mL of Roneparstat or heparin. (D and E) Logistic inhibition curve of
Roneparstat or heparin treatment during VSV-eGFP-SARS-CoV-2 infection. (F) Schematic representation of
the genome of VSV-eGFP-SARS-CoV-1. VSV G was deleted from the VSV genome, and the SARS-CoV-1 S
gene was inserted between the M and L genes in the VSV genome, which resulted in the construction of
replication-competent VSV-eGFP-SARS-CoV-1. Monolayers of Vero-E6 cells were infected with VSV-eGFPSARS-CoV-1 at an MOI of 0.1 in the presence or absence of various doses of Roneparstat or heparin for 1
h. At 10 h postinfection, infected cells (GFP1) were quantiﬁed by a Cytation 5 microscope. (G and H)
Representative ﬂuorescence images of Vero-E6 cells infected with VSV-eGFP-SARS-CoV-1 in the presence
of 0, 0.012, 0.2, and 3.125 m g/mL of Roneparstat or heparin. (I and J) Logistic inhibition curve of
Roneparstat or heparin treatment during VSV-eGFP-SARS-CoV-1 infection. (K and L) Representative
images of immunostaining from SARS-CoV-2 (strain USA-WA1/2020) (400 PFU)-infected monolayers of
Vero-E6 cells. Antibodies speciﬁc to the SARS-CoV-2 spike (S) or nuclear (N) protein were used to identify
SARS-CoV-2-infected cells under various Roneparstat or heparin treatment conditions (0, 0.0015, 0.097,
and 6.25 m g/mL). (M and N) Logistic inhibition curve of Roneparstat or heparin treatment during SARSCoV-2 infection. Error bars represent the SEM. *, P , 0.05; **, P , 0.01; ***, P , 0.001 (2-tailed
distribution, homoscedastic Student’s t test for 2 groups or 1-way ANOVA for multiple comparisons).
April 2022 Volume 96 Issue 7

10.1128/jvi.00057-22

5

Downloaded from https://journals.asm.org/journal/jvi on 02 June 2022 by 128.252.174.220.

Heparanase Blockade in COVID-19

Journal of Virology

FIG 2 Roneparstat-mediated blockade of infection is dependent on HSPGs. (A to C) The Vero-E6 (A), Jurkat (B), or THP-1 (C) cell line was treated with
various doses of Roneparstat (0, 25, 50, 100, and 200 m g/mL) for 24 h. Subsequently, cell viability was examined using a CellTiter-Blue viability assay. (D)
Jurkat-LTR-Luc reporter cells cocultured with irradiated HTLV-1-producing MT-2 cells in the presence or absence of various doses (10, 100, and 200 m g/mL)
of Roneparstat for 48 h. Infectivity (percent) was quantiﬁed via luciferase assays. (E and F) HIV-1-LTR-Luc reporter cells were pretreated overnight with
Roneparstat (10, 100, and 200 m g/mL), followed by HIV-1 (CXCR4- or CCR5-tropic strain) infection for 24 h. Infectivity (percent) was quantiﬁed via luciferase
assays. (G and H) U87/X4 or U87/R5 target cells were infected with the VSVg-pseudotyped virus VSVg-HIV-1Denv-luc for 48 h in the presence or absence of
Roneparstat (10 and 100 m g/mL). Infectivity (percent) was quantiﬁed via luciferase assays. Error bars represent the SEM. *, P , 0.05; **, P , 0.01; ***,
P , 0.001; NS, not signiﬁcant (2-tailed distribution, homoscedastic Student’s t test for 2 groups or 1-way ANOVA for multiple comparisons).

the expression levels of HPSE, along with inﬂammatory cytokine genes such as IL6, TNF, IL1B,
and CCL2, increased with the disease severity of COVID-19 (Fig. 3C to G). Inﬂammatory cytokines such as IL-6 and tumor necrosis factor alpha (TNF-a) are critical players during the
inﬂammation phase of COVID-19 (24). Spearman’s correlation coefﬁcient test between HPSE
and the inﬂammatory cytokine genes IL6, TNF, IL1B, and CCL2 showed a signiﬁcant positive
correlation (Fig. 3H to K). These data conﬁrmed that HPSE is upregulated in the macrophages of COVID-19 patients and is associated with inﬂammatory cytokine release.
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FIG 3 The HPSE gene is upregulated in the BALF of COVID-19 patients and correlates with the expression of inﬂammatory cytokine genes in macrophages.
(A, top) Alignment of major BALF cell clusters by UMAP across control (n = 4), moderate COVID-19 (n = 3), and severe COVID-19 (n = 6) samples. (Bottom)
UMAP presentation showing the HPSE gene expression levels across control, moderate COVID-19, and severe COVID-19 samples. (B) Heat map of
differential HPSE gene expression of different cell types by each COVID-19 sample. Cell markers (cell types are identiﬁed by signature genes) for each cell
type are deﬁned as follows: CD68 for macrophages, TPSB2 for mast cells, MS4A1 for B cells, IGHG4 for plasma cells, KLRD1 for natural killer (NK) cells,
FCGR3B for neutrophils, LILRA4 for plasmacytoid dendritic cells (pDC), CD3D for T cells, TPPP3 and KRT18 for epithelial cells, and CD1C and CLEC9A for
myeloid dendritic cells (mDC). (C to G) Expression levels of HPSE, IL6, TNF, IL1B, and CCL2 by BALF macrophages across healthy control, moderate COVID-19,
and severe COVID-19 samples. (H to K) Correlations between HPSE expression and the expression of IL6, TNF, IL1B, and CCL2. Error bars represent the SEM.
*, P , 0.05; **, P , 0.01; ***, P , 0.001 (2-tailed distribution, homoscedastic Student’s t test for 2 groups or 1-way ANOVA for multiple comparisons; a
Spearman correlation coefﬁcient test was adopted to determine statistically signiﬁcant correlations between two groups).

Inhibition of HPSE enzyme activity with Roneparstat decreases inﬂammatory
cytokine release induced by SARS-CoV-2 spike protein in human primary macrophages.
The binding of SARS-CoV-2 to host cell coreceptors is mediated by the receptor binding domain (RBD) in the S1 subunit of the spike protein. To test whether S1 protein is
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sufﬁcient to trigger inﬂammatory cytokine release and HPSE expression, we used a
macrophage challenge model. Human primary macrophages were differentiated
from monocytes from healthy human donors in vitro and subsequently challenged
with SARS-CoV-2 S1 protein overnight (Fig. 4A). Gene expression analysis by quantitative PCR (qPCR) revealed a signiﬁcant upregulation of HPSE, IL6, TNF, CCL2, and
IFNG after S1 protein challenge (Fig. 4B). To evaluate whether heparanase can regulate the expression of inﬂammatory cytokine genes such as IL-6, in parallel with S1
protein challenge, we treated macrophages with various doses of active recombinant
human heparanase for 12 h and examined the IL-6 expression level by qPCR.
Treatment with exogenous heparanase induced elevated levels of IL-6 expression, at
levels similar to those seen with S1 protein stimulation (Fig. 4C). Next, to examine
whether HPSE blockade could suppress the induction of inﬂammatory cytokines, we
challenged macrophages with S1 protein, in the presence or absence of various
doses of Roneparstat. Indeed, treatment with Roneparstat resulted in a dose-dependent reduction in the expression of inﬂammatory cytokine genes such as IL6, TNF,
CCL2, and IFNG (Fig. 4D to G). Using a ﬂow cytometry-based multiplex inﬂammatory
cytokine array, we showed that HPSE blockade with Roneparstat also signiﬁcantly
attenuated the protein levels of multiple inﬂammatory cytokines, including IL-6, TNFa, IL-10, IL-1 b , IL-23, IL-33, and IL-12p70 (Fig. 4H to N). In contrast, no signiﬁcant
changes were seen in interferon gamma (IFN-g), IFN-a2, monocyte chemoattractant
protein 1 (MCP-1), IL-8, IL-17A, and IL-18 (data not shown). These experiments demonstrated that S1 protein alone is sufﬁcient to induce the upregulation of heparanase, which promotes the production of inﬂammatory cytokines. HPSE blockade with
Roneparstat dampens inﬂammatory cytokine release induced by SARS-CoV-2 S1 protein in macrophages.
SARS-CoV-2 spike protein-induced inﬂammatory cytokine release is partially
mediated by HPSE. Heparanase is important for macrophage activation (25). To further investigate the proinﬂammatory role of HPSE in macrophages in the context of
SARS-CoV-2, we knocked down the HPSE gene in the human macrophage cell line
THP-1 using short hairpin RNA (shRNA) with a 60% average knockdown efﬁciency (Fig.
5A). THP-1 cell-derived macrophages were challenged with S1 protein (0.5 m g/mL). The
knockdown of HPSE in THP-1 macrophages prevented the induction of IL6 or IL1B
gene expression (Fig. 5B and C). At the protein level, using a ﬂow cytometry-based
multiplex inﬂammatory cytokine array, we found marked increases in multiple inﬂammatory cytokines (IL-6, TNF-a, MCP-1, and IL-1B) in the conditioned medium from the
S1-stimulated THP-1 cells but at much lower levels in the stimulated HPSE knockdown
lines (Fig. 5D to H). These data suggest that HPSE plays an important role in the induction of inﬂammation cytokines in macrophages upon S1 protein challenge.
Roneparstat decreases SARS-CoV-2 spike protein-induced inﬂammatory cytokine
release via NF-jB signaling. NF-k B signaling is a master regulator of inﬂammation,
which regulates the transcription of several cytokines (26). To test whether the induction of the inﬂammatory cytokines by SARS-CoV-2 spike protein was dependent on NFk B signaling, human macrophages were pretreated with the NF-k B inhibitor BAY-117082 (BAY) for 1 h, followed by S1 protein challenge. Treatment with BAY suppressed
S1 protein-induced inﬂammatory cytokine gene expression (IL6, TNF, IL1B, and CCL2) in
a dose-dependent manner (Fig. 6A to D). At steady state, cytosolic NF-k B p65 is retained
in an inactive form and is targeted by E3 ligases for degradation (27). In response to proinﬂammatory signals, p65 translocates from the cytoplasm to the nucleus, where it is stabilized and activates the transcription of inﬂammatory cytokine genes. In macrophages, p65
also induces its own transcription, further increasing the nuclear occupancy of p65 and,
consequently, cytokine production (26). Immunostaining of p65 in primary macrophages
stimulated with S1 protein showed an overall increase of p65, with a signiﬁcant increase in
nuclear occupancy, as measured by the nuclear mean ﬂuorescence intensity (MFI).
Cotreatment with Roneparstat showed a dose-dependent reduction in nuclear p65 (Fig. 6E
and F). The reduction of nuclear and cytoplasmic NF-k B (p65) was also conﬁrmed by
Western blotting (Fig. 6G to I). Together, these data demonstrated that in macrophages
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FIG 4 Inhibition of HPSE by Roneparstat decreases inﬂammatory cytokine release induced by the SARS-CoV-2 spike protein. (A) Experimental design of
human primary monocyte-derived macrophages challenged with SARS-CoV-2 spike (S1) protein. (B) qPCR detection of the transcription of the HPSE, IL6,
TNF, CCL2, and IFNG genes in macrophages challenged with S1 protein (0.5 m g/mL) for 12 h. (C) qPCR detection of the transcription of IL-6 in macrophages
challenged with S1 protein (0.5 m g/mL) or various doses (100, 200, and 300 ng/mL) of recombinant active heparanase (rHPSE) for 12 h. (D to G) qPCR
detection of the transcription of the IL6, TNF, CCL2, and IFNG genes in macrophages cotreated with S1 protein (0.5 m g/mL) and various doses of
Roneparstat (50 and 200 m g/mL) for 12 h. (H) Conditioned medium was collected from the macrophages cotreated with S1 protein (0.5 m g/mL) and
various doses of Roneparstat (100 and 200 m g/mL) for 24 h. Inﬂammatory cytokines were quantiﬁed using a ﬂow cytometry-based multiplex cytokine array.
Fold changes of the secreted inﬂammatory cytokines were normalized to the values for the untreated control and are presented in a heat map. (I to N)
Absolute concentrations of secreted TNF-a, IL-6, IL-10, IL-1 b , IL-33, and IL-23 were calculated based on standard curve ﬁtting. Error bars represent the SEM.
*, P , 0.05; **, P , 0.01; ***, P , 0.001 (2-tailed distribution, homoscedastic Student’s t test for 2 groups or 1-way ANOVA for multiple comparisons).
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FIG 5 SARS-CoV-2 S1-induced inﬂammatory cytokine release depends on HPSE expression. Control (shLuc) or HPSE knockdown (KD) THP-1-derived
macrophages were challenged with S1 protein (0.5 m g/mL) for 12 h. (A to C) Transcription levels of HPSE (A), IL6 (B), and IL1B (C) were examined by qPCR.
(D) Conditioned medium was collected from the THP-1 macrophages treated with S1 protein (0.5 m g/mL) for 24 h. Inﬂammatory cytokines were quantiﬁed
using a ﬂow cytometry-based multiplex cytokine array. Fold changes of the secreted inﬂammatory cytokines were normalized to the values for the
untreated control and are presented in a heat map. (E to H) Absolute concentrations of secreted IL-6 (E), TNF-a (F), MCP-1 (G), and IL-1 b (H) were
calculated based on standard curve ﬁtting. Error bars represent the SEM. *, P , 0.05; **, P , 0.01; ***, P , 0.001 (2-tailed distribution, homoscedastic
Student’s t test for 2 groups or 1-way ANOVA for multiple comparisons).

challenged with SARS-CoV-2 S1 protein, Roneparstat treatment reduced NF-k B-dependent
induction of inﬂammatory cytokines.
DISCUSSION
To date, COVID-19 has caused over 5 million deaths worldwide. However, while the
development and deployment of vaccines are ongoing, effective therapy for COVID-19
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FIG 6 Roneparstat decreases SARS-CoV-2 spike protein-induced inﬂammatory cytokine release via NF-k B signaling. Human primary macrophages were
pretreated with an NF-k B inhibitor (NFkBi) (BAY) for 1 h, followed by S1 protein (0.5 m g/mL) challenge for 12 h. (A to D) Transcription levels of IL6 (A), TNF

(Continued on next page)
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is still urgently needed. In this study, we sought to evaluate the role of heparanase in
COVID-19 disease pathology and to evaluate Roneparstat, a chemically modiﬁed heparin that is a potent inhibitor of heparanase enzyme activity without anticoagulant activity, as a novel dual-targeting therapy for COVID-19. Many viruses, including SARSCoV-2, are known to utilize heparan sulfate (HS) to attach to the host target cell. In line
with these ﬁndings, we found that treatment with Roneparstat signiﬁcantly decreased
infection by coronaviruses, including SARS-CoV-2 and SARS-CoV-1, as well as retroviruses, including HTLV-1 and HIV-1, in vitro. From scRNA-seq analyses of bronchoalveolar lavage ﬂuid (BALF) samples from COVID-19 patients, we found that heparanase
gene (HPSE) expression was signiﬁcantly upregulated in CD681 bronchial macrophages
in COVID-19 patients with moderate and severe disease. To evaluate the role of heparanase in macrophages and inﬂammation in COVID-19, we stimulated human macrophages with SARS-CoV-2 S1 protein and found signiﬁcant induction of heparanase and
other key inﬂammatory cytokines. Importantly, we found that pharmacological blockade of heparanase with Roneparstat suppressed inﬂammatory cytokine production in
response to SARS-CoV-2 S1 protein challenge, through decreased NF-k B signaling.
A recent structural analysis revealed that heparin, a structural analog of HS, can
bind to the receptor binding domain (RBD) of the SARS-CoV-2 S1 protein, inducing a
distinct conformational change (28). The interaction between heparin and the SARSCoV-2 spike protein was also conﬁrmed by competitive binding assays, showing that
heparin can bind at high-picomolar afﬁnity (29). Our data revealed that both heparin
and Roneparstat potently decreased infection by SARS-CoV-2 in Vero-E6 cells. Using
the VSV-eGFP-SARS-CoV-2 chimeric virus, we observed similar potency of Roneparstat
or heparin in blocking infectivity, indicating that one of the main mechanisms leading
to reduced infectivity could be through Roneparstat competitive disruption of SARSCoV-2 spike protein binding to cell surface HS. An extended analysis of Roneparstat
and infectivity using other RNA viruses, including VSV-eGFP-SARS-CoV-1 chimeric virus
and pathogenic HIV-1 and HTLV-1, also showed the efﬁcacy of Roneparstat in reducing
infection. Importantly, Roneparstat failed to decrease the infectivity of VSVg-HIV-lucDenv, an HSPG-independent pseudotyped HIV-1. These data suggest that the reliance
on HSPGs to enter the target cell may be a common phenomenon among these RNA
viruses. Although beyond the scope of this study, we are designing experiments to
determine if Roneparstat interferes with the RBD of the SARS-CoV-2 spike protein, as
has been observed with heparin.
Heparanase regulates the availability of HS on the cell surface or within the extracellular matrix. Upregulation of heparanase has been primarily studied for its role in cancer progression (12). In recent years, accumulating evidence suggests that HPSE is also
involved in viral disease pathogenesis (30). In HSV-1-associated disease, the upregulation of HPSE after HSV-1 infection promoted virus shedding and the production of
proinﬂammatory cytokines (31, 32). Another recent study reported by Agelidis et al.
demonstrated that cells lacking HPSE expression are intrinsically resistant to HSV-1
infection. In the corneal infection model, HPSE knockout mice also had decreased virus
titers and associated inﬂammation (33). The role of heparanase in viral pathogenesis is
likely due to the multiple effects of this enzyme. Once new virus is produced, during its
egress from the cell, it can be trapped on the cell surface by heparan sulfate-bearing
cell surface proteoglycans, including syndecan-1. Heparanase stimulated by viral infection degrades cell surface heparan sulfate chains, thereby facilitating the release of the
FIG 6 Legend (Continued)
(B), IL1B (C), and IFNG (D) were assessed by qPCR. (E) Representative NF-k B (p65) immunostaining of human primary macrophages cotreated with S1
protein (0.5 m g/mL) and various doses of Roneparstat (50 and 100 m g/mL) for 24 h. (Top) DAPI; (middle) p65 (Alexa Fluor 488 [AF-488]); (bottom) merged.
(F) Quantiﬁcation of the mean ﬂuorescence intensity (MFI) of the nuclear p65 signal. Seven to ten high-power ﬁelds were captured and quantiﬁed under
each treatment condition. (G) Western blots of cytoplasmic and nuclear p65 in human primary macrophages treated with various doses of Roneparstat (50
and 100 m g/mL) and S1 protein (0.5 m g/mL) for 30 min. Blots were reprobed with anti-TBP antibody as a loading control for nuclear fractions and b -actin
for the cytoplasmic fractions. (H and I) Cytoplasmic and nuclear p65 levels were quantiﬁed by NF-k B p65/ b -actin and p65/TBP ratios, respectively. a.u.,
arbitrary units. Error bars represent the SEM. *, P , 0.05; **, P , 0.01; ***, P , 0.001 (2-tailed distribution, homoscedastic Student’s t test for 2 groups or 1way ANOVA for multiple comparisons).
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virus bound to those chains (30). An additional role for heparanase in viral egress lies
in its ability to stimulate the shedding of heparan sulfate proteoglycans from the cell
surface. It was previously demonstrated that the expression of heparanase by myeloma
cells upregulates extracellular signal-regulated kinase (ERK) signaling, leading to the
expression of the syndecan-1 sheddase matrix metalloproteinase 9 (MMP-9) (34).
Similarly, during HSV-1 infection, heparanase induces the expression of MMP-3 and
MMP-7, which leads to the shedding of cell surface syndecan-1 and the virus that is
bound to the heparan sulfate chains (35).
The addition of puriﬁed recombinant heparanase resulted in macrophage activation
and the upregulation of inﬂammatory cytokines, including IL-6 (36). Macrophages from
heparanase knockout (Hpa-KO) mice also expressed lower levels of inﬂammatory cytokines (e.g., IL-6, TNF-a, and IL-1 b ) (25), and the overexpression of Hpse exacerbated
inﬂammatory cytokine production in an ulcerative colitis model (13). Buijsers et al.
recently reported that elevated plasma levels of heparanase were detected in hospitalized patients with COVID-19 (16), but the source of heparanase has not been deﬁned.
In our studies, single-cell RNA-seq analysis of cells harvested from BALF enabled us to
identify macrophages as the primary source of heparanase. In a recent report by
Abdelmoaty et al. (37), it was shown that human macrophages were infected by live
SARS-CoV-2. Although infection of macrophages by SARS-CoV-2 is restrictive without
evidence of replication, mature virions showed long persistence (14 days after initial
exposure). In addition, persistent SARS-CoV-2 components in macrophages induced
the production of multiple proinﬂammatory cytokines such as IL-6, IL-1 b , and TNF-a,
similar to what we have shown with the SARS-CoV-2 S1 protein, and HPSE knockdown
in THP-1-derived macrophages resulted in a signiﬁcant attenuation of inﬂammatory
cytokines, highlighting the pivotal role of HPSE in the induction of inﬂammation.
Together, these data demonstrated the multifaceted roles of heparanase in both infection and inﬂammation.
A subset of COVID-19 patients progress to a severe stage, characterized by dysregulated inﬂammatory cytokine release that causes tissue injury, acute respiratory distress
syndrome (ARDS), and death. The hyperinﬂammatory state in patients with severe
COVID-19 resembles cytokine release syndrome (CRS), which is seen in patients receiving chimeric antigen receptor (CAR) T-cell therapy (5). The overproduction of IL-6 by
monocytes/macrophages has emerged as a key driver of CRS. Tocilizumab, a humanized monoclonal antibody against the IL-6 receptor, has been evaluated in large
randomized clinical trials. While some trials (RECOVERY and REMAP-CAP trials) showed
a survival beneﬁt, others, including the COVACTA trial, showed a limited or no beneﬁt
in patient mortality (38, 39). These disparate results may be due to multiple factors,
such as the timing of the treatment, the patient population, and the use of glucocorticoids. This may also indicate that targeting a single inﬂammatory cytokine may not be
sufﬁcient to suppress the overall inﬂammatory disease progression in COVID-19. In our
cytokine screening of a panel of common proinﬂammatory cytokines, we found elevations of numerous inﬂammatory cytokines other than IL-6 after S1 protein challenge
that were blocked by Roneparstat, suggesting that targeting heparanase could be a
viable therapeutic approach for inhibiting inﬂammatory cytokine release in COVID-19.
The NF-k B signaling pathway is the main regulator of the production of inﬂammatory cytokines during the innate immune response. Wang et al. reported that the
SARS-CoV-1 spike protein induced IL-6 and TNF-a production by activating NF-k B (40).
IL-6 is the main stimulator of STAT3, which allows the full activation of the NF-k B signaling pathway (41). TNF-a also promotes the activation of noncanonical NF-k B signaling. In the case of hyperinﬂammation, these interactions result in a vicious cycle of NFk B hyperactivation fueling the production and release of more inﬂammatory cytokines.
In our study, Western blot assays as well as immunoﬂuorescence staining of NF-k B
(p65) in macrophages showed increased p65 expression in both the cytoplasmic and
nuclear compartments, suggesting that the spike protein is a strong activator of NF-k B
signaling. Treatment with Roneparstat decreases both the cytoplasmic and nuclear
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p65 levels, suggesting that heparanase inhibition could prevent the induction of the
expression of p65. Studies are under way to evaluate NF-k B signaling in infection and
pathogenesis models in vivo.
Pulmonary activation of coagulation pathways is common in severe COVID-19, evidenced by the elevated levels of D-dimer and ﬁbrin degradation product (FDP) (42).
Patients with severe COVID-19 are at an increased risk of venous thromboembolism
and microthrombosis. Disseminated intravascular coagulation (DIC) was reported in
71.4% of nonsurvivors versus 0.6% of survivors among patients diagnosed with COVID19 (43). Anticoagulant therapy such as heparin was recommended for COVID-19
patients with hypercoagulable syndromes. From one retrospective study, treatment
with low-molecular-weight heparin (LMWH) resulted in lower serum IL-6 levels in
COVID-19 patients (44). No therapeutic beneﬁt of heparin was observed in COVID-19
patients with critical disease (45). In COVID-19 patients with moderate disease, therapeutic doses of heparin increased the probability of survival and reduced the use of
cardiovascular or respiratory organ support, compared with the usual-care thromboprophylaxis (46). The therapeutic dose of heparin, however, is associated with a 10 to 15%
risk of signiﬁcant bleeding. Factors increasing the risk of bleeding include older age, anemia, recent trauma or surgery, hypertension, and renal insufﬁciency. Many of these risk factors are common in patients with severe COVID-19. In contrast, Roneparstat is a chemically
modiﬁed heparin that caused little to no bleeding complications in a phase I clinical trial at
all doses tested. In our infectivity assay, Roneparstat showed activity comparable to that of
unfractionated heparin in the SARS-CoV-2 infectivity assay. An open-label, multicenter
phase I clinical trial (ClinicalTrials.gov identiﬁer NCT01764880) was carried out to evaluate
the safety and tolerability of Roneparstat in patients with relapsed/refractory multiple myeloma. Roneparstat was well tolerated in patients, with no dose-limiting toxicities (20).
Future studies are under way to examine the tolerability and efﬁcacy of Roneparstat in
SARS-CoV-2 animal models.
COVID-19 consists of two main pathogenic phases, progressing from the initial
infection response phase dominated by SARS-CoV-2 entry and replication to the
inﬂammatory response phase dominated by the host immune response. The current
standard COVID-19 therapy includes antiviral therapy with remdesivir and anti-inﬂammatory drugs such as dexamethasone to decrease disease severity but showed less
optimal results in reducing mortality. While cytokines produced during the infection
may contribute to the worsening of the disease, they could also be important for the
antimicrobial response. Therefore, blocking of inﬂammatory cytokine release alone at
the early stage may impair the clearance of the virus and lead to delayed recovery
from the disease. This might partially explain the poorer outcomes in mild COVID-19
patients receiving dexamethasone in the RECOVERY trial (ClinicalTrials.gov identiﬁer
NCT04381936) (47). The dual-targeting effect of Roneparstat on both viral infection
and macrophage-mediated inﬂammatory cytokine release (Fig. 7) and its safe proﬁle in
patients could be advantageous in this setting. Beyond the scope of COVID-19, HPSE
may also play a role in other RNA virus-mediated diseases, such as respiratory syncytial
virus (RSV) (48). Studies are under way to evaluate Roneparstat in RSV-associated
pathogenesis. In conclusion, our preclinical data suggest that heparanase is a target
for SARS-CoV-2 pathogenesis and that Roneparstat could serve as a novel dual-targeting agent for COVID-19.
MATERIALS AND METHODS
Cell lines and viral particles. Experiments involving HTLV-1 were performed under biosafety level 2
(BSL2) practices and procedures. Experiments involving HIV-1 and SARS-CoV-2 were performed at BSL3
facilities under BSL3 practices and procedures. The Jurkat-LTR-Luc reporter line, the HTLV-1-transformed
lymphocytic cell line MT-2, and the human monocyte cell line THP-1 (ATCC) were maintained in RPMI
1640 supplemented with 10% fetal bovine serum (FBS). The Vero-E6 (ATCC) cell line and the human
293T cell line were maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with 10%
FBS. The Jurkat-LTR-Luc reporter cell line is a human T-cell leukemia cell line engineered to express ﬁreﬂy luciferase under the control of the HTLV-1 long terminal repeat, as described previously (49). The
TZM-Blue HIV-1 reporter cell line is a HeLa cell clone that expresses CD4, CXCR4, CCR5, and the ﬁreﬂy
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luciferase gene driven by the HIV-1 long terminal repeat (50). TZM-Blue and Lenti-X 293T cells (TaKaRa
Bio) were maintained in DMEM supplemented with 10% FBS.
Human primary peripheral blood mononuclear cells (PBMCs) were acquired from deidentiﬁed
donors at the Mississippi Valley Regional Blood Center. As determined by Washington University’s HRPO
(Human Research Protection Ofﬁce) in 2009, these anonymous human blood cells are not considered
human subject research. PBMCs were isolated using Ficoll-Paque Plus density gradient medium, at a
density of 1.077 g/mL (catalog number 10771; Sigma), according to the manufacturer’s instructions.
HIV-1 NLHX (CXCR4-tropic) or HIV-1 NLYU2 (CCR5-tropic) viral particles were made by transfecting
293T cells with HIV-1 NLHX or HIV-1 NLYU2 plasmids, as previously described (50).
The replication-competent vesicular stomatitis virus (VSV)-SARS-CoV-2 chimeric virus expressing
enhanced green ﬂuorescent protein (eGFP) (VSV-eGFP-SARS-CoV-2), in which VSV G was replaced with
the SARS-CoV-2 S gene, was generously provided by Sean Whelan (51). A similar VSV-SARS-CoV-1 chimeric virus (VSV-eGFP-SARS-CoV-1) was also provided by Sean Whelan. Both VSV-eGFP-SARS-CoV-2 and
VSV-eGFP-SARS-CoV-1 were grown in Vero-E6 cells.
Human macrophage differentiation. Human CD141 monocytes were puriﬁed from human PBMCs
of healthy donors using CD141 beads (catalog number 130-050-201; Miltenyi Biotec), according to the
manufacturer’s instructions. Puriﬁed CD141 monocytes were cultured in minimal essential medium
alpha (a-MEM) supplemented with 10% FBS and 20 ng/mL human recombinant macrophage colonystimulating factor (M-CSF) (catalog number 574804; BioLegend). Fresh media with M-CSF were changed
every 3 days until the cells reached 70 to 80% conﬂuence (days 12 to 14).
Human THP-1-derived macrophage differentiation. THP-1 macrophage differentiation was initiated by exposing the cells to 5 ng/mL phorbol-12-myristate-13-acetate (PMA) (catalog number 1656129-8; Sigma-Aldrich) for 72 h. Subsequently, PMA was removed, and THP-1-derived macrophages were
washed one time with phosphate-buffered saline (PBS) before S1 protein (0.5 m g/mL; GenScript,
Piscataway, NJ) challenge. RNA or medium supernatants were harvested 12 h or 24 h after S1 protein
challenge, respectively.
Inhibitors/drugs. Roneparstat (previously named SST0001 or 100 NA,RO-H) (18, 52) was kindly supplied by Leadiant Biosciences (Rome, Italy). A stock concentration of 50 mg/mL was prepared by solubilizing the drug in sterile water and stored at room temperature (up to 30 days). Heparin sodium salt
from porcine intestinal mucosa (catalog number H3149; Sigma) was resuspended in PBS at a stock concentration of 25 mg/mL and stored at 4°C. The NF-k B inhibitor BAY 11-7082 (catalog number B5556;
Sigma) was solubilized in dimethyl sulfoxide (DMSO) at a stock concentration of 50 mM and stored at
220°C.
SARS-CoV-2 infectivity assay. SARS-CoV-2 (USA-WA1/2020) was obtained from BEI Resources. USAWA1/2020 was isolated from an oropharyngeal swab from a COVID-19 patient in Washington. Viral
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FIG 7 Schema of the potential dual-targeting actions of Roneparstat in COVID-19. The pathogenesis
of COVID-19 consists of two pathogenic phases: (i) the early infection phase, characterized by SARSCoV-2 viral entry, replication, and spread, and (ii) the later inﬂammation phase, characterized by
aberrant proinﬂammatory cytokine release that leads to tissue damage, ARDS, or even death. During
the initial infection phase, Roneparstat decreases viral infection by competing with HSPG-dependent
viral entry. During the inﬂammation phase, HPSE blockade via Roneparstat attenuates SARS-CoV-2mediated inﬂammatory cytokine release from macrophages, through disruption of NF-k B signaling.
Together, this study demonstrated the potential use of Roneparstat as a dual-targeting therapy for
COVID-19 to decrease viral infection and dampen the proinﬂammatory immune response mediated
by macrophages.
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stocks were generated by infecting Vero-E6 cells at an MOI of 0.1 PFU. Both Roneparstat and heparin
were subjected to 4-fold serial dilutions from 200 m g/mL to 0.003 m g/mL, and each dilution was mixed
with the same volume of SARS-CoV-2 (16,000 PFU/mL). Next, the mixture was transferred to conﬂuent
Vero-E6 cells in 48-well plates. The ﬁnal concentrations of Roneparstat and heparin were ;100 to
0.0015 m g/mL, and the virus dose was 400 PFU/well. After a 1-h inoculation at 37°C in a CO2 incubator,
the mixture was removed from each well, and fresh DMEM supplemented with 2% FBS and a different
dose of Roneparstat or heparin (;100 to 0.0015 m g/mL) was added (200 m L/well). At 24 h postinfection,
the cell culture supernatant from each well was harvested for virus titration by a plaque assay on VeroE6 cells. The half-maximal inhibitory concentration (IC50) was calculated based on the viral titer from the
plaque assay. The infected Vero-E6 cell monolayer was ﬁxed with 300 m L of 4% neutral buffered formaldehyde at room temperature for 2 h, followed by immunostaining with anti-SARS-CoV-2 S or N antibody.
Percent inhibition was calculated with the formula % inhibition = 100 2 titertreated/titeruntreated  100. The
curve ﬁt and IC50 were generated by Prism 8 [log(inhibitor) versus normalized response 2 variable
slope].
VSV-SARS-CoV-2 infectivity assay. Each compound was diluted serially, 4-fold, from 50 m g/mL to
0.0122 m g/mL and incubated with VSV-eGFP-SARS-CoV-2 or VSV-eGFP-SARS-CoV-1 for 1 h at 37°C. The
compound-virus mixtures were used to inoculate Vero-E6 cells (MOI = 0.1) in 96-well plates and incubated at 37°C for 1 h, after which the mixture was replaced with 200 m L of DMEM with 2% FBS containing 50 m g/mL to 0.0122 m g/mL of each compound. At 10 h postinoculation, cells were ﬁxed in 2% formaldehyde for 30 min at room temperature and replaced with PBS. Viral infectivity was measured by
automated enumeration of GFP-positive cells from captured images using a Cytation 5 automated ﬂuorescence microscope (BioTek) and analyzed using Gen5 data analysis software (BioTek). Percent inhibition was calculated as 100 2 green cells with compound treatment/green cells with no compound
treatment  100. The IC50 of each peptide was determined by Prism 8 [log(inhibitor) versus normalized
response 2 variable slope].
Plaque assays for SARS-CoV-2, VSV-eGFP-SARS-CoV-2, and VSV-eGFP-SARS-CoV-1. Conﬂuent
Vero-E6 cells in 12-well plates were infected with 10-fold serial dilutions of SARS-CoV-2, VSV-eGFP-SARSCoV-2, or VSV-eGFP-SARS-CoV-1 in FBS-free DMEM. After absorption for 1 h at 37°C, the inoculum was
removed, and 1 mL of a MEM overlay containing 0.25% low-melting-point agarose, 2% FBS, 0.12% sodium bicarbonate, 25 mM HEPES (pH 7.7), 2 mM L-glutamine, 100 m g/mL of streptomycin, and 100 U/mL
of penicillin was added. After incubation at 37°C for 2 days, wells were ﬁxed with 10% neutral buffered
formaldehyde for 2 h, the overlay was removed, the cells were stained with 0.05% (wt/vol) crystal violet,
and the plaques were counted.
HTLV-1 infectivity assay. The infectivity of HTLV-1 was measured using the Jurkat-LTR-Luc reporter
cell line as described previously (53). Brieﬂy, the HTLV-1-producing cell line MT-2 was irradiated using an
XCell50 cell irradiator (Kubtec Scientiﬁc) at 60 Gy and incubated with Jurkat-LTR-Luc reporters at a ratio
of 20,000 MT-2 cells to 100,000 Jurkat-LTR-Luc cells (1:5 ratio). Various doses of Roneparstat were added
at the same time of infection. At 24 or 48 h postinfection, cells were collected and lysed in luciferase cell
culture lysis buffer (Promega). Luciferase activities were measured and presented as relative light units
(RLU).
HIV-1 infectivity assay. TZM-Blue reporter cells were pretreated with the inhibitor in a 48-well plate
for 24 h, and CXCR4- or CCR5-tropic HIV-1 strains were then added in the presence of various doses of
Roneparstat or the vehicle. At 48 h postinfection, infected TZM-Blue cells were collected and lysed with
0.2% Triton X-100 in PBS. Luciferase activities were measured and presented as RLU. For VSVg-HIV-1-luc
pseudotyped virus production, 293T cells were cotransfected with pHIV-1-luc/Denv and pVSVg, and virus was collected at 72 h posttransfection, as previously described (54, 55). U87/X4 or U87/R5 cells were
seeded into a 48-well plate (2  104 cells per well) and infected with VSVg-HIV-1-luc in the presence or
absence of various amounts of Roneparstat. Infected cells were lysed in a solution containing 100 m L
PBS and 0.5% Triton X-100 at 48 h postinfection and examined for luciferase activity. Each infection/
treatment was run in triplicates.
Lentivirus production and HPSE knockdown THP-1 cells. Lenti-X 293 cells were transfected with
psPAX2, PMD2.G and plasmid of interest using Lipofectamine 3000 (Invitrogen), and the supernatant was harvested at 24 h posttransfection. For HPSE KD, short hairpin RNA (shRNA) constructs in pLKO.1 puro vectors
were obtained from Sigma-Aldrich (luciferase shRNA [shLuc], 59-CAGAATCGTCGTATGCAGTGA-39; HPSE
shRNA 1, 59-GAGGAGAAGTTACGGTTGGAA-39; HPSE shRNA 2, 59-CCCAAGAAGGAATCAACCTTT-39; HPSE
shRNA 3, 59-GCGAGGAGATTCTGTAAACTT-39). THP-1 cells were infected with lentivirus overnight in the presence of 10 m g/mL protamine sulfate. At 24 h postinfection, transduced cells were selected with 2 m g/mL puromycin for 3 days. RNA or conditioned medium was harvested from macrophages challenged with SARSCoV-2 S1 protein (0.5 m g/mL) for 12 h or 24 h, respectively.
Western blotting. Nuclear and cytoplasmic protein lysates were isolated from human macrophages
using the NE-PER nuclear and cytoplasmic extraction kit (Thermo Scientiﬁc) supplemented with Halt protease inhibitor cocktail (Thermo Scientiﬁc) according to the manufacturer’s protocol. Samples were separated on 4 to 20% Mini-Protean TGX precast protein gels (Bio-Rad) by SDS-PAGE and transferred onto
Immobilon-P polyvinylidene diﬂuoride (PVDF) membranes (EMD Millipore) overnight at 4°C. Membranes
were incubated with NF-k B p65 (clone D14E12), TATA binding protein (TBP) (clone D5C9H), or b -actin
(clone 13E5) primary antibodies (1:1,000; Cell Signaling), followed by horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibody (1:2,000; Cell Signaling). All antibodies were diluted in 1 Trisbuffered saline (TBS)–Tween (TBST) with 5% bovine serum albumin (BSA). Bands were developed by
enhanced chemiluminescence and quantiﬁed using ImageJ software.
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Human macrophage immunocytochemistry (ICC) staining. Human PBMCs were resuspended in
a-MEM (supplemented with 10% FBS and human recombinant M-CSF at 20 ng/mL) and seeded onto
coverslips (number 1.5 coverslip, 13-mm glass diameter; VWR) in 24-well plates. Cells were cultured for 2
days, and the nonadherent cells were then removed by sequential washes with Dulbecco’s PBS (DPBS)
(Gibco). Fresh media with M-CSF were changed every 2 to 3 days until the cells reached 70 to 80% conﬂuence (days 5 to 7). Cells were challenged with SARS-CoV-2 S1 (0.5 m g/mL) protein, with or without various doses of Roneparstat (50 m g/mL and 100 m g/mL), for 24 h. For immunostaining, each well was ﬁxed
with 4% paraformaldehyde (15 min at room temperature), followed by two washes with ice-cold TBS.
Each coverslip was subsequently incubated with 0.2% Triton X-100 (Sigma) for 10 min, 10% goat serum
(Cell Signaling) for 30 min, anti-human p65 primary antibody (1:700; Cell Signaling) overnight at 4°C,
and Alexa Fluor 488-conjugated anti-rabbit antibody (1:400; Jackson ImmunoResearch) for 1 h, and
nuclei were counterstained with 49,6-diamidino-2-phenylindole (DAPI) (catalog number 422801;
BioLegend) for 5 min. Coverslips were mounted onto glass slides (VWR) with ProLong Gold antifade
mountant (catalog number P10144; Life Technologies).
Confocal microscopy and nuclear p65 quantiﬁcation. Slides were imaged with a confocal microscope (FluoView1200; Olympus) with a 40 water immersion lens objective. Seven to ten high-power
ﬁelds were captured under each treatment condition. To quantify the nuclear p65 signal, captured
images were analyzed using the Fiji imaging processing package with standard plug-ins (56). DAPI staining was used to determine nuclear segmentation and masking. Brieﬂy, for each high-power ﬁeld, binary
image masks were created using a DAPI-positive single-channel image to deﬁne the nuclear region of interest (ROI). The image calculator was used to subtract the DAPI mask from the original p65 single-channel images to create images with p65 staining within the nuclear ROI. Image measurements of the p65
mean ﬂuorescence intensities (MFIs) within the nuclear ROI were then determined by the mean gray
value within the DAPI mask using an empirically derived threshold.
Quantitative real-time PCR (qRT-PCR) and primers. RNA was extracted from cells using an RNeasy
kit (Qiagen), and cDNA was generated with qScript cDNA supermix (Quanta Bio). qPCR was performed
with PerfeCTa SYBR green supermix reagent (Quanta Bio) on the Bio-Rad CFX96 machine, as previously
described (57). Primers designed for qPCR are as follows: HPSE forward primer 59-CTCTCTG
CTCTGCCATCTTTAG-39 and reverse primer 59-CCTCTGGTTGCTATGAGGTTT-39, IL6 forward primer 59CTTCCATCCAGTTGCCTTCT-39 and reverse primer 59-CTCCGACTTGTGAAGTGGTATAG-39, TNF forward
primer 59-CCAGGGACCTCTCTCTAATCA-39 and reverse primer 59-TCAGCTTGAGGGTTTGCTAC-39, CCL2
forward primer 59-TCATAGCAGCCACCTTCATTC-39 and reverse primer 59-CTCTGCACTGAGATCTT
CCTATTG-39, IFNG forward primer 59-ATGTCCAACGCAAAGCAATAC-39 and reverse primer 59-ACCTCG
AAACAGCATCTGAC-39, HPRT forward primer 59-AGAATGTCTTGATTGTGGAAGA-39 and reverse primer 59ACCTTGACCATCTTTGGATTA-39, IL1B forward primer 59-CAAAGGCGGCCAGGATATAA-39 and reverse
primer 59-CTAGGGATTGAGTCCACATTCAG-39, and GAPDH forward primer 59-AGGTCGGTGTGAACGG
ATTTG-39 and reverse primer 59-TGTAGACCATGTAGTTGAGGTCA-39.
Multiplex cytokine array. A bead-based human inﬂammatory cytokine array was performed using
LEGENDplex human inﬂammation panel 1 (BioLegend). Human primary macrophages were cultured for 24 h
in the presence of S protein, with or without various doses of Roneparstat (50 to 200 m g/mL). Twenty-ﬁve
microliters of the conditioned medium from various conditions was used to measure the secreted cytokines
in each sample, according to the instructions from the manufacturer. The measurement was performed on a
FACSCalibur ﬂow cytometer (BD), and the data were analyzed using LEGENDplex software (BioLegend).
Single-cell RNA sequencing analysis. The R package Seurat was used for data scaling, dimensionality
reduction, clustering, differential expression analysis, and visualization (58). First, the gene-barcode matrix was
normalized using the LogNormalize method in the Seurat NormalizeData function with default parameters.
Next, 2,000 variable genes were selected using the vst selection method in the Seurat FindVariableFeatures
function. Subsequently, the ﬁltered features were scaled using the Seurat ScaleData function with default parameters, where the two variables nCount_RNA and percent.mito were regressed out during the scaling process. The principal-component analysis (PCA) was performed using variable genes, and the top 50 principal
components were used to perform UMAP, which maps cells into the two-dimensional space for visualization.
Next, a k-nearest-neighbor-based clustering analysis was performed on the PCA-reduced data to identify cell
clusters using the Seurat FindClusters function with the resolution set to 1.2. Based on the UMAP reduction
results, the DimPlot and FeaturePlot functions in Seurat were respectively used to visualize the BALF cell clusters and highlight the HPSE gene expression levels across healthy control, moderate COVID-19, and severe
COVID-19 samples (Fig. 3A).
The FindAllMarkers function in Seurat was used to perform the differential expression analysis (59).
The Model-Based Analysis of Single Cell Transcriptomics (MAST) package was used in FindAllMarkers.
For each of the major cell types, the averaged differential HPSE gene expression level was calculated for
each COVID-19 sample relative to all of the healthy control cells (Fig. 3B). The HPSE gene in each cell
type was considered signiﬁcant for a COVID-19 sample if the P value was ,0.05, adjusted by the false
discovery rate using Bonferroni correction.
Macrophages were reintegrated with a new Seurat object. Macrophages from all samples were integrated using the top 50 dimensions of canonical correlation analysis and PCA, where the parameter
k.ﬁlter was set to 115. Next, the average expression levels of the HPSE gene and the inﬂammatory cytokine genes IL6, TNF, IL1B, and CCL2 were calculated using the Seurat AverageExpression function with
default parameters. Similarly, average expression levels for each of the healthy control, moderate
COVID-19, and severe COVID-19 samples were generated (Fig. 3C).
Statistical analysis. Experiments were analyzed using two-tailed Student’s t test (2 groups), oneway analysis of variance (ANOVA) (.2 groups or repeated measures), or two-way ANOVA (two variables;
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the P value refers to the interaction) using Prism 8 (GraphPad Software, Inc.). A nonparametric Spearman
correlation coefﬁcient test was adopted to determine statistically signiﬁcant correlations between two
groups. Results were considered to reach signiﬁcance at a P value of #0.05 and are indicated with asterisks in the ﬁgures (*, P # 0.05; **, P # 0.01; ***, P # 0.001; ****, P # 0.0001). Data are presented as mean
values; error bars represent the standard errors of the means (SEM).
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